Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Below 200-Day Moving Average - Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.30 and traded as low as $2.11. Oramed Pharmaceuticals shares last traded at $2.12, with a volume of 21,385 shares changing hands.

Analyst Ratings Changes

Separately, Wall Street Zen cut Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th.

Oramed Pharmaceuticals Stock Up 5.4%

The stock has a market cap of $96.00 million, a P/E ratio of 21.36 and a beta of 1.65. The business has a 50-day simple moving average of $2.20 and a 200-day simple moving average of $2.29.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last announced its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The business had revenue of $2.00 million during the quarter. On average, analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. BML Capital Management LLC raised its stake in shares of Oramed Pharmaceuticals by 14.3% in the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock valued at $6,464,000 after purchasing an additional 376,841 shares in the last quarter. Boothbay Fund Management LLC raised its stake in shares of Oramed Pharmaceuticals by 2.0% in the fourth quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after purchasing an additional 16,857 shares in the last quarter. Peapod Lane Capital LLC raised its stake in shares of Oramed Pharmaceuticals by 11.0% in the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after purchasing an additional 24,985 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Oramed Pharmaceuticals by 143.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 70,190 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Oramed Pharmaceuticals by 35.3% in the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 17,510 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.